250 Major Companies Still Use SPLC to Screen Donations, Despite KKK Funding Scandal
Maria Becker
Originally published April 24, 2026
Related Companies
Latest Content
Final NIH Report on Multi-Million Dollar Olson-Kennedy Study Shows Puberty Blockers Don’t Help Kids
August 28, 2026WASHINGTON, D.C. — The final report for the National Institutes of Health (NIH)-funded “Trans Youth Care” study led by Dr. Johanna Olson-Kennedy of Children’s Hospital Los Angeles was finally made public this month, after the government watchdog organization Oversight Project was forced to sue the agency for its release. The multi-year, multi-million-dollar observational study examining physiological and psychological effects of puberty blockers and sex-denying hormones on youth with gender dysphoria has concluded, and the final report was submitted January 6, 2026. This taxpayer-funded research was intended to evaluate longer-term impacts of these interventions. Its conclusions reinforce a growing body of evidence that puberty blockers lack reliable proof of benefit for children and carry long-known risks to bone density, fertility, sexual function, and development. “The mass medical experiments on children need to stop,” said Doug Napier, Executive Chairman and CEO of 1792 Exchange. “These findings align with the emerging consensus that there is no benefit, but significant risks of harm to children, including impacts on bone density, fertility, sexual function, and cognitive development.” “The Cass Review in the United Kingdom, the Finland study, and the U.S. Department of Health and Human Services’ own 2025 peer-reviewed report on pediatric gender dysphoria all underscore the serious concerns about the impacts of these experiments. And this study is yet another nail in the coffin for transgender ideology,” Napier continued. The data on puberty blockers for children continue to show no significant positive mental or emotional health gains. Earlier peer-reviewed and preprint analyses from the same “Trans Youth Care” cohort—tracking depression symptoms, emotional health, …
Companies Reviewing GLP-1 Coverage Should Also Review Transgender Healthcare Coverage
August 20, 2026According to reports earlier this month, Starbucks is ending GLP-1 coverage for its employees. Under its new healthcare plan, Starbucks will no longer cover prescription drugs used for weight loss, but it will continue to cover comprehensive transgender healthcare interventions, including reconstructive surgical procedures and puberty blockers, for covered dependents. Employers are pulling back on GLP-1 coverage largely for the same reason they are reconsidering other benefits: to adjust to rising healthcare costs. RxBenefits reports that GLP-1 drugs cost roughly $1,000–$1,500 per month, while SHRM estimates employers often shoulder 70–100% of prescription drug costs. With GLP-1s now accounting for around 20% of prescription drug spending and the number of users accelerating, employers face a limited set of choices: tighten eligibility requirements, shift more of the cost to employees or customers, or eliminate coverage altogether. If companies can reasonably reconsider GLP-1 coverage because of cost, uncertain return on investment, and broader questions over what an employer-sponsored health plan should cover, why should other expensive medical benefits, such as transgender medical interventions, be exempt from similar scrutiny? According to February 2026 data from the Human Rights Campaign, more than 550 major companies, including Starbucks, offer comprehensive transgender healthcare benefits to employees and covered dependents. While …
1792 Exchange Applauds Apple for Improving Responsible Mineral Sourcing in East Africa
August 10, 2026WASHINGTON, D.C. — The Eagle Freedom Alliance released a shareholder engagement letter recognizing Apple for advancing more transparent and accountable mineral sourcing in East Africa. The letter was signed by investors and advisors connected to Apple shareholdings and highlighted Apple’s support for traceable tantalum supply chains. Signatories included 1792 Exchange, Innovest, GuideStone, Praxis, and the Eagle Freedom Fund. The letter notes: “As leading innovators in fighting human trafficking and committed shareholders in Apple Inc., we are writing to express our deep appreciation and admiration for Apple’s exemplary work in forging an ethical and forward-thinking path in the sourcing of key minerals from East Africa. In particular, we commend Apple’s leadership in the Responsible Mineral Initiative and its efforts to bring transparency to the supply chain. We applaud your efforts to ensure that Apple’s supply chain reflects the highest standards of human rights and recognize your work with Africa’s only tantalum refinery, PowerX Ltd., and its vertically integrated mining operation, PowerM Ltd., in Rwanda.” Apple’s leadership deserves recognition. Its approach demonstrates how a company can use its purchasing power to improve supply-chain transparency, reduce exploitation risks, strengthen resilience, and protect long-term shareholder value. Many companies still fail to adequately account for labor abuses deep within their supply chains, which exposes them to significant legal, reputational, operational, and financial …
Microsoft Directs Benevity to Drop SPLC Filter
July 22, 2026After engagement from Inspire Investing and others, Microsoft has directed Benevity to stop using the SPLC’s “hate map” to filter nonprofits from its employee gift-matching program. In its “Max the Match” document, Microsoft states any nonprofit organization that “verifies its 501c3 or equivalent status will be available to Microsoft employees.” The Daily Signal highlighted several organizations, including the 1792 Exchange, engaging companies on behalf of shareholders to ensure charitable giving is viewpoint neutral. The 1792 Exchange is pleased to work alongside Inspire Investing, Bowyer Research, the Heritage Foundation, and many others in this important work. 1792 Exchange created this resource to track how companies are responding to the growing controversy surrounding the SPLC and Benevity and encourages companies that have made changes to their charitable giving programs to disclose those changes to their customers and shareholders.
ESG Rating Inconsistencies and Their Ideological Ends
July 7, 2026Allen Mendenhall’s recent piece on MSCI ranking SpaceX in the same ESG tier as Russia asks a fair question: how does a rocket company advancing American innovation get scored the same as a state waging war? Unbeknownst to many, inconsistencies are common when it comes to ESG portfolios and ratings. In 2022, S&P dropped Tesla from its S&P 500 ESG Index while ExxonMobil landed in the top ten. The EV maker scored worse on an “Environmental, Social, Governance” rating than a major oil company. In fact, according to MIT Sloan’s Aggregate Confusion Project, ESG ratings from major agencies correlate at only about 0.61. Compare that to credit ratings from Moody’s and S&P, which agree 99% of the time. Companies often receive vastly different ESG rating scores from ratings providers, even ones that share a pro-ESG bias. These are the kinds of inconsistencies that led Elon Musk, CEO of the second-largest electric vehicle manufacturer in the world, to declare that ESG is a scam. Mendenhall concludes himself: the SpaceX rating shows ESG functioning less as “socially conscious investing” and more as “a mechanism for advancing ideological ends.”